Profil
Rebecca Lin is currently a Director at Shanghai Rarestone Health Tech Group Co., Ltd. and a Senior Partner & Co Head at Eight Roads Capital Advisors (CHINA) since 2021.
Education includes an undergraduate degree from Shenzhen University conferred in 1994 and an MBA from The Wharton School of the University of Pennsylvania conferred in 2000.
Postes actifs de Rebecca Lin
| Sociétés | Poste | Début |
|---|---|---|
Eight Roads Capital Advisors (CHINA)
Eight Roads Capital Advisors (CHINA) Investment ManagersFinance Functions as an alternative investment manager | Private Equity Investor | 01/06/2007 |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and supplies rare disease pharmaceutical products & provides medical services | Directeur/Membre du Conseil | - |
Formation de Rebecca Lin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Shenzhen University
Shenzhen University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eight Roads Capital Advisors (CHINA)
Eight Roads Capital Advisors (CHINA) Investment ManagersFinance Functions as an alternative investment manager | Finance |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and supplies rare disease pharmaceutical products & provides medical services | Health Technology |
















